Video

David W. Goodman, MD: Adult ADHD Challenges During COVID-19

Author(s):

Adults with ADHD may face a number of challenges during the ongoing pandemic.

The coronavirus disease 2019 (COVID-19) has made things challenging for patients with psychiatric disorders like attention deficit/hyperactivity disorder (ADHD).

While stress, social isolation, and shelter-in-place orders can exacerbate symptoms of depression and anxiety, the situation can also wreak havoc on the symptoms of impulsivity association with ADHD. And that impulsivity could lead the individual to be in situations where they are more susceptible to contracting the virus.

How COVID-19 impacts ADHD treatment and care was a major topic during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference with several abstracts and plenaries planned to discuss the topic.

In an interview with HCPLive®, David W. Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, explained how ADHD patients may have struggled greatly in the last 10 months and how that struggle could have both short- and long-term issues.

Not only are ADHD patients more likely to contract the virus because of the symptoms that come along with the disorder, they may struggle with the at home situation that could harm interpersonal relationships.

Goodman said one of the concerns is adult ADHD patients with children may have to juggle too many things between work, maintaining a home, and the virtual schooling of their children.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
© 2024 MJH Life Sciences

All rights reserved.